You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Outlook Therapeutics to implement 1-for-8 reverse stock split
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Market Intelligence Platform
Outlook Therapeutics Inc.'s board approved a 1-for-8 reverse split of its common stock.
The Cranbury, N.J.-based biopharmaceutical company's common shares will begin trading on a reverse split-adjusted basis from March 18 on the Nasdaq Capital Market.
Outlook's shareholders have already approved the plan.
American Stock Transfer & Trust Co. LLC, which is the company's transfer agent, is acting as the exchange agent for the stock split.